West Pharmaceutical Services (WST) FY2025 10-K Annual Report
West Pharmaceutical Services (WST) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
West Pharmaceutical Services FY2025 10-K Analysis
Business Overview
- • Core business: Manufacturer of integrated containment and delivery systems for injectable drugs, including proprietary packaging and contract manufacturing
- • Emphasis on patient-centric self-injection devices combined with connected health technologies for improved treatment adherence
Risk Factors
- • Regulatory risk: U.S. tariffs and retaliatory tariffs in operational jurisdictions; impact on supply chain currently not material but dynamic and monitored closely
- • Macroeconomic risk: $572.2 million cash held outside the U.S., exposing liquidity to foreign exchange volatility and global economic conditions
West Pharmaceutical Services FY2025 Key Financial MetricsXBRL
Revenue
$3.1B
▲ +6.3% YoY
Net Income
$494M
▲ +0.2% YoY
Gross Margin
35.9%
▲ +140bp YoY
Operating Margin
19.0%
▼ -67bp YoY
Net Margin
16.1%
▼ -97bp YoY
ROE
15.5%
▼ -282bp YoY
Total Assets
$4.3B
▲ +17.2% YoY
EPS (Diluted)
$6.79
▲ +1.5% YoY
Operating Cash Flow
$755M
▲ +15.5% YoY
Source: XBRL data from West Pharmaceutical Services FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on West Pharmaceutical Services
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.